Frazier Life Sciences XI, L.P., 10% Owner at Attovia Therapeutics, Inc. (ATTO), bought 588,235 shares at $17.00 ($10.0M) on 2026-08-06, disclosed to the SEC on 2026-08-06.
Frazier Life Sciences XI, L.P. executed the largest insider purchase in the company's history, acquiring 588,235 shares at $17.00 on August 6, 2026, signaling strong conviction in the stock's near-term trajectory.
The stock is currently trading at $20.645, representing a 9.25% discount to its 52-week high of $22.75, indicating the market may be overlooking the recent insider accumulation.
Insider cluster: This is the largest insider purchase ever recorded for ATTO, suggesting a high-conviction bet by a major shareholder.
Valuation risk: The stock is trading at a premium to its 52-week high, which could limit upside if the company fails to meet market expectations.
Negative factors outweigh the positive ones.